Skip to navigation Skip to content



Ten-Year Followup of People with Suspicious MRIs without MS Symptoms (“RIS”) Suggests Half Develop MS

July 7, 2020

In a global study of 451 people described as having “radiologically isolated syndrome” (RIS, a rare phenomenon in which people with no symptoms of MS have MRI scans that show specific areas of MS-like damage), 51.2% went on to develop MS within ten years. Several factors made some more likely to develop MS, so further defining these factors should help guide decisions about whether treating specific people with RIS is justified. Trials are now underway in people with RIS to determine if disease-modifying therapies will prevent or delay the development of MS. 
  • A global team of collaborators has been tracking people with RIS to see which go on to develop MS, and whether there is a way to predict this outcome in advance to guide treatment decisions.
  • In this study, factors associated with increased risk of later developing MS included younger age, having signs of spinal fluid proteins known as “oligoclonal bands,” having MRI lesions in the spinal cord or lower back part of the brain (infratentorial), and newly active lesions on follow-up MRI scans.
  • Trials underway or planned in people with RIS include one testing teriflunomide (Aubagio®, Genzyme Sanofi) that is recruiting outside of the U.S., one testing dimethyl fumarate (Tecfidera®, Biogen) that is ongoing and no longer recruiting, and one testing a tuberculosis vaccine that is planned in Italy.
 “Radiologically Isolated Syndrome: 10‐Year Risk Estimate of a Clinical Event” by Christine Lebrun‐Frenay MD, PhD (Nice Cote d’Azur University) and colleagues was published June 4, 2020 in Annals of Neurology.

About Multiple Sclerosis

Multiple sclerosis is an unpredictable disease of the central nervous system. Currently there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS.


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.